Vertex Pharmaceuticals (VRTX) Non-Current Deferred Tax Liability (2009 - 2018)
Vertex Pharmaceuticals (VRTX) posted quarterly Non-Current Deferred Tax Liability of $9.4 million for Q3 2018, down 11.87% year-over-year from $10.7 million in Q3 2017, and up 0.85% quarter-over-quarter from $9.3 million in Q2 2018.
Vertex Pharmaceuticals (VRTX) Non-Current Deferred Tax Liability (2009 - 2018) Analysis & Trends
Vertex Pharmaceuticals' Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $9.4 million for Q3 2018.
- In Q3 2018, Non-Current Deferred Tax Liability fell 11.87% year-over-year to $9.4 million; the TTM figure through Sep 2018 stood at $9.4 million (down 11.87% YoY), while the FY2017 annual figure was $6.3 million, down 95.27% from the prior year.
- Non-Current Deferred Tax Liability for Q3 2018 stood at $9.4 million, up from $9.3 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $136.6 million in Q2 2017, with the low at $6.3 million in Q4 2017.
- The 5-year median for Non-Current Deferred Tax Liability is $111.2 million (2015), against an average of $74.8 million.
- The sharpest annual moves came in 2016 and 2017: Non-Current Deferred Tax Liability soared 643.78% in 2016, then plunged 95.27% in 2017.
- Vertex Pharmaceuticals' Non-Current Deferred Tax Liability stood at $15.0 million in 2014, then jumped by 631.75% to $110.1 million in 2015, then advanced by 21.78% to $134.1 million in 2016, then plunged by 95.27% to $6.3 million in 2017, then soared by 48.46% to $9.4 million in 2018.
- Business Quant data shows VRTX's Non-Current Deferred Tax Liability at $9.4 million in Q3 2018, $9.3 million in Q2 2018, and $9.6 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 9.41 Mn |
| Sep 30, 2018 | 9.41 Mn |
| Jun 30, 2018 | 9.34 Mn |
| Jun 30, 2018 | 9.34 Mn |
| Mar 31, 2018 | 9.64 Mn |
| Mar 31, 2018 | 9.64 Mn |
| Dec 31, 2017 | 6.34 Mn |
| Dec 31, 2017 | 6.34 Mn |
| Sep 30, 2017 | 10.68 Mn |
| Sep 30, 2017 | 10.68 Mn |
| Jun 30, 2017 | 136.65 Mn |
| Jun 30, 2017 | 136.65 Mn |
| Mar 31, 2017 | 135.40 Mn |
| Mar 31, 2017 | 135.40 Mn |
| Dec 31, 2016 | 134.06 Mn |
| Dec 31, 2016 | 134.06 Mn |
| Sep 30, 2016 | 133.27 Mn |
| Sep 30, 2016 | 133.27 Mn |
| Jun 30, 2016 | 132.81 Mn |
| Jun 30, 2016 | 132.81 Mn |